BRIEF—Horizon and C4XD enter into drug discovery collaboration

Horizon Discovery Group has entered into an exclusive target discovery partnership with fellow UK-listed firm C4X Discovery, aimed at delivering potential therapies for colorectal and lung cancer.

The partnership seeks to validate novel synthetic oncology targets identified using CRISPR-Cas9 technology by Horizon. C4XD will use Conformetrix, a proprietary 4D shape-based chemistry technology to discover pre-clinical drug candidates.

C4XD will fund the work and will out-license resulting candidates to clinical development partners, with Horizon receiving an undisclosed share of future revenues.